Cove Private Wealth LLC Buys New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cove Private Wealth LLC purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 440 shares of the biopharmaceutical company's stock, valued at approximately $313,000.

Several other large investors also recently added to or reduced their stakes in the stock. International Assets Investment Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 86,013.3% in the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company's stock worth $926,078,000 after acquiring an additional 879,916 shares during the last quarter. Worldquant Millennium Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth about $127,489,000. Icon Wealth Advisors LLC lifted its stake in Regeneron Pharmaceuticals by 18,342.0% in the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company's stock worth $79,874,000 after purchasing an additional 75,569 shares during the last quarter. State Street Corp boosted its position in shares of Regeneron Pharmaceuticals by 1.3% during the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company's stock valued at $5,153,603,000 after buying an additional 61,277 shares during the period. Finally, Epoch Investment Partners Inc. boosted its position in shares of Regeneron Pharmaceuticals by 57.7% during the second quarter. Epoch Investment Partners Inc. now owns 163,296 shares of the biopharmaceutical company's stock valued at $171,629,000 after buying an additional 59,745 shares during the period. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Down 1.7 %

REGN traded down $11.65 on Monday, hitting $681.58. The company had a trading volume of 1,107,622 shares, compared to its average volume of 678,713. The stock has a market capitalization of $74.90 billion, a price-to-earnings ratio of 16.87, a P/E/G ratio of 1.60 and a beta of 0.10. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The stock has a fifty day moving average price of $738.60 and a 200-day moving average price of $948.80. Regeneron Pharmaceuticals, Inc. has a 12-month low of $666.25 and a 12-month high of $1,211.20.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on REGN shares. Morgan Stanley decreased their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating for the company in a research note on Friday, November 1st. Leerink Partnrs lowered Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 24th. BMO Capital Markets lowered their target price on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an "outperform" rating for the company in a research note on Friday, November 1st. Wells Fargo & Company reduced their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a research note on Friday, January 10th. Finally, Leerink Partners reiterated a "market perform" rating and set a $1,077.00 price objective (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. One analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $1,015.38.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.